Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Pichon

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Cancer Research|April 15, 1990
Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coliJ F Prud'homme, A Jolivet, M F Pichon, et al.
European Journal of Gynaecological Oncology|February 26, 1998
Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinationsN Callet, C C Cohen-Solal Le Nir, E Berthelot, et al.
The International Journal of Biological Markers|January 11, 2003
Prognostic value of CA 15.3 kinetics for metastatic breast cancerB De La Lande, K Hacene, J L Floiras, et al.
The International Journal of Biological Markers|April 14, 2004
Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patientsM Saghatchian, S Guepratte, K Hacene, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 29, 2000
Comparison of Cyfra 21-1 and SCC assays in head and neck tumoursA Banal, K Hacene, E Berthelot-Ruff, et al.
BJU International|March 14, 2002
Serum chromogranin-A in advanced prostate cancerM Ferrero-Poüs, A M Hersant, A Pecking, et al.
Histopathology|January 1, 1984
Relationship between ultrastructure and receptor content of human primary breast cancerV Le Doussal, M F Pichon, C Pallud, et al.
Gynecologic Oncology|March 11, 2008
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric studyJ M Riedinger, N Eche, J P Basuyau, et al.
Histopathology|September 1, 1993
Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumoursC Pallud, V Le Doussal, M F Pichon, et al.
Anticancer Research|May 4, 2005
Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumoursC Pallud, J M Guinebretiere, S Guepratte, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Cancer Research|April 15, 1990
Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coliJ F Prud'homme, A Jolivet, M F Pichon, et al.
European Journal of Gynaecological Oncology|February 26, 1998
Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinationsN Callet, C C Cohen-Solal Le Nir, E Berthelot, et al.
The International Journal of Biological Markers|January 11, 2003
Prognostic value of CA 15.3 kinetics for metastatic breast cancerB De La Lande, K Hacene, J L Floiras, et al.
The International Journal of Biological Markers|April 14, 2004
Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patientsM Saghatchian, S Guepratte, K Hacene, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 29, 2000
Comparison of Cyfra 21-1 and SCC assays in head and neck tumoursA Banal, K Hacene, E Berthelot-Ruff, et al.
BJU International|March 14, 2002
Serum chromogranin-A in advanced prostate cancerM Ferrero-Poüs, A M Hersant, A Pecking, et al.
Histopathology|January 1, 1984
Relationship between ultrastructure and receptor content of human primary breast cancerV Le Doussal, M F Pichon, C Pallud, et al.
Gynecologic Oncology|March 11, 2008
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric studyJ M Riedinger, N Eche, J P Basuyau, et al.
Histopathology|September 1, 1993
Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumoursC Pallud, V Le Doussal, M F Pichon, et al.
Anticancer Research|May 4, 2005
Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumoursC Pallud, J M Guinebretiere, S Guepratte, et al.
Pageof 5